FOLFOXIRI + Panitumumab

DRUG2 trials

Sponsors

AIO-Studien-gGmbH, Gruppo Oncologico del Nord-Ovest

Conditions

Metastatic Colo-rectal CancerMetastatic Colorectal Cancer

Phase 2

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

CompletedNCT01328171

AIO-Studien-gGmbHMetastatic Colorectal Cancer

Start: 2011-04-30End: 2022-01-31Updated: 2023-06-15

FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer

CompletedNCT01358812

Gruppo Oncologico del Nord-OvestMetastatic Colo-rectal Cancer

Start: 2010-03-31Updated: 2015-03-11

Related Papers

Impact of anti-EGFR and anti-VEGF antibodies on survival in BRAF <sup>V600E</sup> mutated metastatic colorectal cancer: A pooled analysis of eight clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).

Journal of Clinical Oncology2025-05-28

BRAF-mutant metastatic colorectal cancer: Prognostic and predictive value of primary tumor location—A pooled analysis of the AIO studies FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI.

Journal of Clinical Oncology2022-06-01

Histopathologic Regression and Survival in RAS Wildtype Metastatic Colorectal Cancer Under First-Line Treatment – Subgroup Analysis of the VOLFI Trial (AIO-KRK-0109)

International Journal of Clinical Oncology and Cancer Research2021-01-011 citations

Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2019-05-207 citations

Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI—A randomized, open label, phase-2 study (AIO KRK0109).

Journal of Clinical Oncology2019-05-20

Correlation of histopathologic regression with progression free survival (PFS) in patients (pts) with RAS wildtype metastatic colorectal cancer (mCRC) under fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone: Subgroup analysis of VOLFI (AIO-KRK-0109).

Journal of Clinical Oncology2019-05-20

1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK-0109)

Annals of Oncology2018-10-018 citations

mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109).

Journal of Clinical Oncology2018-05-2016 citations

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

ESMO Open2018-01-0123 citations

Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies.

Journal of Clinical Oncology2016-05-20